T1	intervention 85 94	LA-EP2006
T2	control 100 123	reference pegfilgrastim
T3	total-participants 1001 1004	624
T4	intervention-participants 1112 1115	314
T5	control-participants 1131 1135	 310
T6	eligibility 810 988	patients with breast cancer receiving myelotoxic (neo)adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemotherapy and requiring granulocyte colony-stimulating factor
T8	outcome 1623 1657	nadir of absolute neutrophil count
T9	outcome 1666 1698	incidence of febrile neutropenia
T10	outcome 1769 1800	safety and tolerability profile
T7	outcome 1242 1277	mean duration of severe neutropenia
T11	iv-cont-mean 1366 1370	1.05
T13	iv-cont-sd 1373 1383	1.055 days
T12	cv-cont-mean 1391 1396	1.01 
T14	cv-cont-sd 1398 1408	0.958 days
